Sotigalimab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Sotigalimab
- DrugBank Accession Number
- DB16413
- Background
Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
- IMMUNOGLOBULIN G1 (270-GLUTAMIC ACID, C-TERMINAL-LYSINE-CLIPPED), ANTI-(HUMAN CD40 ANTIGEN) (HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL APX005M .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL APX005M .KAPPA.-CHAIN, DIMER
- Sotigalimab
- External IDs
- APX-005
- APX-005M
- APX005M
- EPI-0050
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- JEA93WJ5DG
- CAS number
- 2305607-45-6
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Locally Advanced Rectal Adenocarcinoma 1 2 Active Not Recruiting Treatment Soft Tissue Sarcoma 1 2 Completed Treatment Esophageal Cancer / Gastroesophageal Cancer (GC) 1 2 Terminated Treatment Cancer / Cancer of the Skin / Melanoma / Metastatic Melanoma / Unresectable Melanoma 1 2 Withdrawn Treatment Ovarian Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 23, 2020 18:12 / Updated at September 15, 2023 10:38